← All trials
NCT05683717
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2023
- Primary completion
- Oct 31, 2026
- Completion date
- Oct 30, 2028
- First posted
- Jan 13, 2023
- Last posted
- Nov 21, 2023
- Enrollment
- 37
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TransThera Biosciences Co., LtdLead sponsor
- Nanjing Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.